Rebecca Shah, of Keele University, highlights the ethical considerations and trade-off between different human rights as she explores the impact of health worker migration.
Edwin Park: "Medicaid Undone? Covering the Safety Net’s New Future" 7.26.17reportingonhealth
Edwin Park's slides from the Center for Health Journalism webinar, "Medicaid Undone? Covering the Safety Net’s New Future," 7.26.17
More info: https://www.centerforhealthjournalism.org/content/medicaid-undone-covering-safety-nets-new-future
Kathleen Nolan: "Medicaid Undone? Covering the Safety Net’s New Future" 7.26.17reportingonhealth
Kathleen Nolan's slides from the Center for Health Journalism webinar, "Medicaid Undone? Covering the Safety Net’s New Future," 7.26.17
More info: https://www.centerforhealthjournalism.org/content/medicaid-undone-covering-safety-nets-new-future
Katherine Hempstead: "Left in Limbo: Obamacare’s Shaky Insurance Exchanges" 6...reportingonhealth
Katherine Hempstead's slides from the Center for Health Journalism webinar, "Left in Limbo: Obamacare’s Shaky Insurance Exchanges," 6.7.17
More info: https://www.centerforhealthjournalism.org/content/left-limbo-obamacares-shaky-insurance-exchanges
The fiscal sustainability of long-term care and its impact on health systems ...OECD Governance
This presentation was made by Tim Muir, OECD, at the 4th meeting of the Joint DELSA/GOV-SBO Network on Fiscal Sustainability of Health Systems, held in Paris on 16-17 February 2015.
Providing Support To Employers And Working Caregivers 6 14 2010 2Elderplanner
Our “Elder Life Planning for Organizations” program allows non-profit and small eldercare enterprises
to offer a comprehensive eldercare program to employers, banks, membership organizations and faith based communities without the significant capital outlay that would otherwise be required.
Edwin Park: "Medicaid Undone? Covering the Safety Net’s New Future" 7.26.17reportingonhealth
Edwin Park's slides from the Center for Health Journalism webinar, "Medicaid Undone? Covering the Safety Net’s New Future," 7.26.17
More info: https://www.centerforhealthjournalism.org/content/medicaid-undone-covering-safety-nets-new-future
Kathleen Nolan: "Medicaid Undone? Covering the Safety Net’s New Future" 7.26.17reportingonhealth
Kathleen Nolan's slides from the Center for Health Journalism webinar, "Medicaid Undone? Covering the Safety Net’s New Future," 7.26.17
More info: https://www.centerforhealthjournalism.org/content/medicaid-undone-covering-safety-nets-new-future
Katherine Hempstead: "Left in Limbo: Obamacare’s Shaky Insurance Exchanges" 6...reportingonhealth
Katherine Hempstead's slides from the Center for Health Journalism webinar, "Left in Limbo: Obamacare’s Shaky Insurance Exchanges," 6.7.17
More info: https://www.centerforhealthjournalism.org/content/left-limbo-obamacares-shaky-insurance-exchanges
The fiscal sustainability of long-term care and its impact on health systems ...OECD Governance
This presentation was made by Tim Muir, OECD, at the 4th meeting of the Joint DELSA/GOV-SBO Network on Fiscal Sustainability of Health Systems, held in Paris on 16-17 February 2015.
Providing Support To Employers And Working Caregivers 6 14 2010 2Elderplanner
Our “Elder Life Planning for Organizations” program allows non-profit and small eldercare enterprises
to offer a comprehensive eldercare program to employers, banks, membership organizations and faith based communities without the significant capital outlay that would otherwise be required.
NHS and social care workforce: meeting our needs now and in the future slidepackThe King's Fund
The second slidepack in this Time to Think Differently series explores the challenges that the health and social care workforce will face in the future, offering practical suggestions to address them.
Time to Think Differently: The case for changeThe King's Fund
Our Time to Think Differently programme has made the case for change and highlighted the trends that will influence the way health and social care is delivered in future.
To help you explore and share this work, we are creating a series of downloadable slidepacks. We hope that they will inform your thinking and discussions about the future of care.
The first pack in this series explores the pressures on the health and social care delivery system and why it needs to change to meet the challenges of the future.
Public Safety, Public Spending: Forecasting America’s Prison Population, 2007...brighteyes
Public Safety, Public Spending: Forecasting America’s Prison Population, 2007-2011 Adam Gelb, Project Director
Public Safety Performance Project
The Pew Charitable Trusts, Pew Center on the States
October 2, 2007
A Comparative Analysis of Prevention and Delinquencybrighteyes
A Comparative Analysis of Prevention and Delinquency - Authors Mary Magee Quinn and Jeffrey Poirier, American Institutes for Research, National Center on Education, Disability,and Juvenile Justice (EDJJ)
Tackling the Tough Topics: The public plan option, employer pay or play, and ...soder145
Presentation by Jean Abraham of the University of Minnesota at the Minnesota Senate Health and Human Services Budget Division hearing in St. Paul, MN, August 18 2009.
NHS and social care workforce: meeting our needs now and in the future slidepackThe King's Fund
The second slidepack in this Time to Think Differently series explores the challenges that the health and social care workforce will face in the future, offering practical suggestions to address them.
Time to Think Differently: The case for changeThe King's Fund
Our Time to Think Differently programme has made the case for change and highlighted the trends that will influence the way health and social care is delivered in future.
To help you explore and share this work, we are creating a series of downloadable slidepacks. We hope that they will inform your thinking and discussions about the future of care.
The first pack in this series explores the pressures on the health and social care delivery system and why it needs to change to meet the challenges of the future.
Public Safety, Public Spending: Forecasting America’s Prison Population, 2007...brighteyes
Public Safety, Public Spending: Forecasting America’s Prison Population, 2007-2011 Adam Gelb, Project Director
Public Safety Performance Project
The Pew Charitable Trusts, Pew Center on the States
October 2, 2007
A Comparative Analysis of Prevention and Delinquencybrighteyes
A Comparative Analysis of Prevention and Delinquency - Authors Mary Magee Quinn and Jeffrey Poirier, American Institutes for Research, National Center on Education, Disability,and Juvenile Justice (EDJJ)
Tackling the Tough Topics: The public plan option, employer pay or play, and ...soder145
Presentation by Jean Abraham of the University of Minnesota at the Minnesota Senate Health and Human Services Budget Division hearing in St. Paul, MN, August 18 2009.
Improving quality of care, using existing assets better and reducing medical ...NHS England
Expo is the most significant annual health and social care event in the calendar, uniting more NHS and care leaders, commissioners, clinicians, voluntary sector partners, innovators and media than any other health and care event.
Expo 15 returned to Manchester and was hosted once again by NHS England. Around 5000 people a day from health and care, the voluntary sector, local government, and industry joined together at Manchester Central Convention Centre for two packed days of speakers, workshops, exhibitions and professional development.
This year, Expo was more relevant and engaging than ever before, happening within the first 100 days of the new Government, and almost 12 months after the publication of the NHS Five Year Forward View. It was also a great opportunity to check on and learn from the progress of Greater Manchester as the area prepares to take over a £6 billion devolved health and social care budget, pledging to integrate hospital, community, primary and social care and vastly improve health and well-being.
More information is available online: www.expo.nhs.uk
A quick description of American and Canadian Healthcare similarities and differences. I was born in Canada and raised in the US, so it was really interesting to me to know the differences between the two and compare to what I remember prior to becoming a US citizen.
An overview of policy issues related to Criminal prosecutions involving HIV transmission by Darryl O'Donnell, NSW Health. This presentation was given at AFAO's May 2009 General Meeting.
An analysis of the potential to achieve expected reductions in life expectancy from recommended interventions (reviewing the implications of a national modelling exercise)
Patricia Latter REF "Routes to Impact" presentation 26/05/2016LIDC
This event, “REF: routes to impact”, aimed to raise awareness among academic members of the multiple routes to impact their research can have. The aim of the evening was to let researchers consider the numerous ways that research can have an impact within an international development context.
Ian thornton REF "Routes to Impact" presentation 26/05/2016LIDC
This event, “REF: routes to impact”, aimed to raise awareness among academic members of the multiple routes to impact their research can have. The aim of the evening was to let researchers consider the numerous ways that research can have an impact within an international development context.
The UK Research Councils will deliver through the GCRF £1.5b in research grants for international development research over the next five years. This funding is new and additional to existing sources of research support like DFID, the Newton Fund, etc., which will continue. The GCRF represents the largest single boost to research council funding in their history and will create an entirely new stream of development research funding across arts, humanities, social and natural sciences, with particular opportunities for interdisciplinary research.
Malcolm Potts Crisis in the Sahel: Where Population and Climate Change Are Co...LIDC
rofessor Malcolm Potts, renowned in the field of public health, gave a one-off keynote lecture for LIDC. The lecture, at the London School of Hygiene and Tropical Medicine, focused on the emerging humanitarian disaster in the Sahel. It has been central to the work of his team for several years.
An Interdisciplinary Perspective on Global Health and the SDGs - Prof. Sir An...LIDC
It is rare that you find an outstanding leader in a particular discipline who has also become as well an international figure in interdisciplinary thinking. Prof Sir Andy Haines is just such a figure.
A former Director of the London School of Hygiene and Tropical Medicine and one of the designers and founders of LIDC about a decade ago, Andy has in recent years developed an international reputation and programme linking our development agenda for global health with the much bigger challenge of sustainability and the threat posed to that by climate change and environmental degradation.
His work has revealed the threats posed to health and well being by environmental change, but has emphasized and identified the positive opportunities, and the co-benefits they can generate.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.